Publication
Focal adhesion kinase inhibitor defactinib enhances olaparib-induced suppression of BRCA-proficient breast cancer cell proliferation.
Hisako Ono, Keiko Taniguchi, Shusuke Yasuda, Mamiko Sukeno, Tomoya Matsui, Yasuto Naoi, Mano Horinaka, Toshiyuki Sakai
Oncology lettersNov 1, 2026PMID 42798981doi:10.3892/ol.2026.15868 PMC13613322Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Poly ADP-ribose polymerase (PARP) inhibitors exhibit high activity for carcinomas with homologous recombination (HR) deficiency, such as BRCA1/2 mutations. PARP inhibitors are primarily administered to patients with breast cancer with BRCA germline mutations; therefore, the use of these inhibitors…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Breast Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.